Articles and White Papers

Articles and white papers on the health care economics of fracture treatment using EXOGEN.

Improved Healing Response in Delayed Unions of the Tibia with Low-Intensity Pulsed Ultrasound: Results of a Randomized Sham-Controlled Trial

BMC Musculoskeletal Disorders,
Schofer MD, Block JE, Aigner J, Schmelz A

In the first Level-I study regarding non-union† heal rates, 51 patients with tibia delayed unions were treated with EXOGEN. Mean improvement in their bone mineral density was 1.34 times greater than that of patients who received sham device treatment.

Full article available at download or at PubMed.gov.

Cost-Effectiveness of Bone Stimulators in the Conservative Treatment of Stable Non-Union Fractures

International Society for Pharmacoeconomics and Outcomes Research, Seventh Annual European Congress, Hamburg, Germany,
Schultz M, Oremus M, Whitman CS, Conway JD

This white paper 23 evaluates the expected cost of treating a non-union* fracture using five fracture stimulation devices. Researchers determine that EXOGEN is the most cost-effective treatment and is optimal for 85% of patients.

Download white paper.

The economics of treating tibia fractures. The cost of delayed unions.

Published in the Bulletin for NYU Hospital for Joint Diseases,
Heckman JD, Sarasohn-Kahn J

In this study,13 researchers compare three economic models for treating a pool of 1,000 patients with tibia fractures. Using EXOGEN in conservative and operative treatment paths resulted in an overall savings of $14.6 million—a reduction in cost that would benefit third-party payers, employers, government agencies and patients.

Full article available for download or at PubMed.gov.

  • High treatment
    compliance21
  • +
  • Proven clinical
    effectiveness2-4
  • > >
  • Successful fracture
    healing outcomes